VIFOR PHARMA, INC.
KING OF PRUSSIA, PA


RELYPSA, INC.
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. We are focused on developing medicines that will change treatment paradigms. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In September 2016, Relypsa became a Vifor Pharma company. Learn more about Vifor Pharma Vifor Fresenius Medical Care Renal Pharma and Relypsa announce Submission of Marketing Authorisation Application Requesting European Approval of Patiromer for treatment of hyperkalemia Soho Flordis International signs an agreement for the acquisition of Potters and the Equazen(TM) brand portfolio from Vifor Pharma Vifor Fresenius Medical Care Renal Pharma: Expansion of product portfolio and establishment of a marketing and sales organisation in Europe Our Mission For Medical Information, Drug Safety Adverse Event Reports and/or Product Quality Complaints:

KEY FACTS ABOUT VIFOR PHARMA, INC.

Company name
VIFOR PHARMA, INC.
Status
Active
Filed Number
F15000005435
FEI Number
26-0893742
Date of Incorporation
December 9, 2015
Age - 10 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://relypsa.com
Phones
(650) 421-9500
(844) 735-9772
(844) 835-8277

VIFOR PHARMA, INC. NEAR ME

Principal Address
1000 First Ave,
Suite 300,
King of Prussia,
PA,
19406,
US

See Also

Officers and Directors

The VIFOR PHARMA, INC. managed by the three persons from King of Prussia, Glattbrugg on following positions: Trea, Vice President, Secr

Matthew Bocchino

Position
Trea Active
From
King of Prussia, PA, PA

Timothy Kanter

Position
Vice President Active
From
King of Prussia, PA, PA

Alex Sigalas

Position
Secr Active
From
Glattbrugg, Gl, Gl





Registered Agent is CT CORPORATION SYSTEM

Address
1200 SOUTH PINE ISLAND ROAD, PLANTATION, FL, 33324

Events

March 2, 2021
AMENDMENT AND NAME CHANGE

Annual Reports

2025
March 28, 2025
2024
April 19, 2024